Literature DB >> 2996750

Liver iron stores and hepatitis B antigen status.

C Cohen, S D Berson, G Shulman, L R Budgeon.   

Abstract

Higher serum iron and ferritin levels noted in hepatitis B antigen (HBAg) carriers than in noncarriers suggests that virus might actively replicate in hepatocytes, stimulate ferritin synthesis, and result in increased liver iron stores. A comparative semiquantitative study of immunohistochemical ferritin (0-12) and hemosiderin (0-9) was performed on 54 normal, 13 cirrhotic, and 70 nonneoplastic livers from patients with hepatocellular carcinoma, in each group, comparing amounts in HBAg-positive and HBAg-negative patients. Mean scores for ferritin and hemosiderin were high in all three groups, normal livers averaging 8.3 and 6, respectively, cirrhotic livers, 8.5 and 7.4, respectively, and carcinoma livers, 5.6 and 6.1, respectively. In each group, there was no significant difference in ferritin and hemosiderin mean scores in HBAg-positive and HBAg-negative patients. The large liver iron stores do not appear to be a consequence of hepatitis B virus infection alone. Their role in the development of hepatocellular carcinoma is still to be elucidated.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2996750     DOI: 10.1002/1097-0142(19851101)56:9<2201::aid-cncr2820560911>3.0.co;2-x

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  3 in total

1.  Successful treatment with lamivudine may correlate with reduction of serum ferritin levels in the patients with chronic hepatitis and liver cirrhosis type B.

Authors:  Shogo Ohkoshi; Akira Yoshimura; Satoshi Yamamoto; Masahiko Yano; So Kurita; Kazuhide Yamazaki; Yo-Hei Aoki; Satoshi Yamagiwa; Hiroto Wakabayashi; Motoya Sugiyama; Tohru Takahashi; Tohru Ishikawa; Yasunobu Matsuda; Takafumi Ichida; Tomoteru Kamimura; Yutaka Aoyagi
Journal:  Hepatol Int       Date:  2008-07-25       Impact factor: 6.047

2.  Sequential changes of serum ferritin levels and their clinical significance in lamivudine-treated patients with chronic viral hepatitis B.

Authors:  Zheng-Wen Liu; Qun-Ying Han; Ni Zhang; Wen Kang
Journal:  World J Gastroenterol       Date:  2004-04-01       Impact factor: 5.742

3.  Radioimmunotherapy of human hepatocellular carcinoma xenografts with 131I-labelled antiferritin antibody.

Authors:  A F Saiful Alam
Journal:  Br J Cancer       Date:  1991-04       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.